Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
ANI Pharmaceuticals Inc ANIP
$79.24
▼ -1.48%
($-1.19)
⬇️ Below Yest. Low
🗓️ Earnings Next Week
Open
$79.65
Prev Close
$80.43
Day Range
$78.24 – $80.38
52W Range
$62.61 – $99.50
Market Cap
$1.80B
P/E (TTM)
19.65
Beta
0.47
EPS (TTM)
$4.29
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2000-05-04 |
| Shares Out. | 22,750,000 |
| Website | anipharmaceuticals.com/ ↗ |
| Phone | 12186343500 |
| Employees | 970 |
| Revenue | $237.5M |
| Gross Profit | $143.9M |
| Net Income | $29.5M |
| Free Cash Flow | $179.1M |
| Total Assets | $1.42B |
| Total Liabilities | $859.7M |
| Equity | $562.3M |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
ANI Pharmaceuticals Inc is a publicly traded company under the ticker symbol ANIP on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)